AcuCort AB (ACUC.ST)

SEK 0.65

(-3.25%)

Total Liabilities Summary of AcuCort AB

  • AcuCort AB's latest annual total liabilities in 2023 was 10.97 Million SEK , up 166.19% from previous year.
  • AcuCort AB's latest quarterly total liabilities in 2024 Q2 was 2.86 Million SEK , down -34.27% from previous quarter.
  • AcuCort AB reported annual total liabilities of 4.12 Million SEK in 2022, up 45.8% from previous year.
  • AcuCort AB reported annual total liabilities of 2.82 Million SEK in 2021, up 157.42% from previous year.
  • AcuCort AB reported quarterly total liabilities of 4.35 Million SEK for 2024 Q1, down -60.33% from previous quarter.
  • AcuCort AB reported quarterly total liabilities of 8.04 Million SEK for 2023 Q3, up 359.66% from previous quarter.

Annual Total Liabilities Chart of AcuCort AB (2023 - 2016)

Historical Annual Total Liabilities of AcuCort AB (2023 - 2016)

Year Total Liabilities Total Liabilities Growth
2023 10.97 Million SEK 166.19%
2022 4.12 Million SEK 45.8%
2021 2.82 Million SEK 157.42%
2020 1.09 Million SEK -45.57%
2019 2.01 Million SEK 6.18%
2018 1.9 Million SEK 9.26%
2017 1.73 Million SEK 190.35%
2016 599.26 Thousand SEK 0.0%

Peer Total Liabilities Comparison of AcuCort AB

Name Total Liabilities Total Liabilities Difference
AlzeCure Pharma AB (publ) 8.22 Million SEK -33.402%
BioGaia AB (publ) 302.84 Million SEK 96.376%
Enzymatica AB (publ) 49.3 Million SEK 77.739%
Enorama Pharma AB (publ) 14.84 Million SEK 26.079%
Gabather AB (publ) 6.87 Million SEK -59.567%
Klaria Pharma Holding AB (publ.) 31.98 Million SEK 65.688%
Moberg Pharma AB (publ) 24 Million SEK 54.284%
Nanexa AB (publ) 36.42 Million SEK 69.871%
Newbury Pharmaceuticals AB (publ) 38.95 Million SEK 71.826%
ODI Pharma AB 10.05 Million SEK -9.121%
Orexo AB (publ) 727.7 Million SEK 98.492%
Probi AB (publ) 181.31 Million SEK 93.947%
Swedencare AB (publ) 2.31 Billion SEK 99.526%
Swedish Orphan Biovitrum AB (publ) 40.16 Billion SEK 99.973%
Toleranzia AB 6.9 Million SEK -58.851%
Vivesto AB 30.45 Million SEK 63.96%